Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	17D0450938	07/06/2026
Name of Provider or Supplier	**Street Address, City, State**	
Caldwell Regional Medical Center	761 West 175th Street South, Caldwell, KS	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on Centers for Medicare & Medicaid Services (CMS) Proficiency Testing (PT) Certification and Survey Provider Enhanced Reporting system and the American Proficiency Institute (API) PT summary reports, the laboratory failed to successfully participate in the CMS approved PT 2025/2026 program under the specialty of Immunohematology, for two consecutive testing events. Refer D2162.
D2162	ABO GROUP AND D(RHO) TYPING CFR(s): 493.859(f)

	(f) Failure to achieve satisfactory performance for the same analyte in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based upon the review of PT results from API and phone interview, the laboratory failed to successfully participate in PT for the regulated analytes: ABO/RHO and D (RHO). Findings: 1. Review of the scores from API for ABO/RHO revealed: a. Third event 2025 score of 90%. b. First event 2026 score of 90%. 2. Review of the scores from API for D (RHO) revealed: a. Third event 2025 score of 80%. b First event 2026 score of 80%. 3. Phone interview with the laboratory supervisor on 7/6/26 at 9:15 a.m. confirmed the laboratory failed to successfully participate in PT for the regulated analytes: ABO/RHO and D (RHO).